Acute Pyelonephritis — Adult

Key Points

• Obtain a urine culture in pyelonephritis because antimicrobial susceptibility should guide definitive therapy.
• Empiric antibiotic choice should reflect sepsis severity, prior urine cultures, recent antibiotic exposure, allergies, organ function, and local resistance.
• Routine CT is unnecessary in a straightforward improving first episode, but imaging is important when obstruction or complications are plausible.
• An infected obstructed collecting system requires urgent drainage; antibiotics alone are inadequate source control.
• Nitrofurantoin and oral fosfomycin do not achieve reliable renal-parenchymal concentrations and should not be used as sole therapy for pyelonephritis.
• Switch from IV to effective oral therapy when the patient is clinically improving and can absorb medication.
• Most improving uncomplicated or complicated pyelonephritis does not require a routine 10- to 14-day course.
• Failure to improve should trigger reassessment for resistance, obstruction, abscess, incorrect diagnosis, or inadequate source control.

Algorithm

1. Assess severity, sepsis, pregnancy status, oral tolerance, and risk for obstruction or resistant pathogens.
2. Obtain urinalysis and urine culture, then begin empiric therapy without unnecessary delay in a sick patient.
3. Treat stable low-risk patients orally when an effective regimen and reliable follow-up are available.
4. Admit or give parenteral therapy for sepsis, inability to tolerate oral therapy, significant comorbidity, pregnancy with concerning illness, or uncertain follow-up.
5. Image promptly when obstruction, stone, abscess, emphysematous infection, severe sepsis, or treatment failure is suspected.
6. Arrange emergent urologic decompression for infected obstruction.
7. Narrow antibiotics to culture results and transition IV therapy to an effective oral agent when improving.
8. Use the shortest effective duration appropriate to the organism, drug, source control, and host factors.

Clinical Synopsis & Reasoning

Patients often report fever, chills, flank or back pain, nausea, vomiting, dysuria, frequency, or urgency, but urinary symptoms can be absent. Older adults may present with delirium or weakness. Examine for costovertebral-angle tenderness, dehydration, sepsis, abdominal or pelvic pathology, and pregnancy. Distinguish pyelonephritis from cystitis, nephrolithiasis, obstructive pyelonephritis, renal abscess, prostatitis, pelvic inflammatory disease, appendicitis, cholecystitis, and musculoskeletal pain. Obtain urinalysis and urine culture before antimicrobials if this does not delay treatment. Pyuria supports urinary inflammation, while bacteriuria and nitrite increase probability but are not required. The 2025 IDSA complicated UTI guideline emphasizes choosing empiric therapy through severity of illness, prior resistant urine isolates, recent antibiotic exposure, patient-specific adverse-effect risks, and relevant local susceptibility data. Patients with sepsis, known stones, urinary obstruction, structural abnormalities, recurrent infection, severe kidney disease, immunocompromise, or failure to improve within about 48 to 72 hours require a lower threshold for imaging. CT is generally the most informative study for complications; ultrasound can identify hydronephrosis and is useful when radiation should be minimized.

Treatment Strategy & Disposition

Mild clinically stable patients who can take oral medication and have reliable follow-up may be treated as outpatients with an effective oral regimen informed by local resistance and prior cultures. Fluoroquinolones can be appropriate where susceptibility is likely and patient risks are acceptable; trimethoprim-sulfamethoxazole is suitable when the organism is known to be susceptible. Oral beta-lactams may be used in selected cases but should be dosed appropriately and have historically had less robust evidence for renal parenchymal infection. For patients requiring initial parenteral therapy, ceftriaxone is a common option; severe sepsis or resistant-organism risk may require cefepime, piperacillin-tazobactam, or a carbapenem based on prior microbiology and local ecology. The 2025 IDSA guideline supports IV-to-oral transition once the patient is improving, can take oral therapy, and an effective oral agent is available. In improving complicated UTI, shorter courses are usually preferred, commonly 5 to 7 days for a fluoroquinolone or about 7 days for a non-fluoroquinolone, while abscess, obstruction, prostatitis, severe immunocompromise, or inadequate source control can require individualized longer treatment. Any infected obstructed system requires urgent urologic decompression with ureteral stent or percutaneous nephrostomy plus antibiotics.

Epidemiology / Risk Factors

• Escherichia coli remains the most common community uropathogen, but resistance patterns vary substantially by region and patient history.
• Risk for resistant gram-negative infection rises with prior resistant isolates, recent antibiotics, health care exposure, urinary devices, and recurrent infection.
• Pyelonephritis is more common in women, but febrile UTI in men deserves attention to prostatitis, obstruction, and structural disease.
• Pregnancy increases the risk and potential consequences of upper urinary infection.
• Diabetes and obstruction increase risk for emphysematous or complicated infection.

Investigations

Empiric Options (Adults)

Pharmacology

Prognosis / Complications

• Most appropriately treated patients improve within 48 to 72 hours.
• Persistent fever alone early in treatment can occur, but worsening physiology or lack of overall improvement requires reassessment.
• Bacteremia does not automatically require prolonged therapy when the patient responds, source control is achieved, and an effective agent is used.
• Obstructed infection can deteriorate rapidly into septic shock without decompression.
• Recurrent pyelonephritis should prompt assessment for stones, reflux, retention, instrumentation, or another predisposing factor.

Patient Education / Counseling

• Take the antibiotic exactly as directed and complete the prescribed effective course unless the treating clinician changes it after cultures.
• Maintain oral hydration according to thirst and medical conditions rather than forcing excessive water intake.
• Seek urgent care for worsening fever, vomiting that prevents medication, fainting, confusion, reduced urine output, or escalating flank pain.
• Tell patients that culture results may require an antibiotic change even if symptoms have begun to improve.
• For recurrent infection, discuss prevention and whether urologic or gynecologic evaluation is indicated rather than repeatedly using empiric antibiotics.

Notes

Pyelonephritis management has shifted away from one-size-fits-all antibiotic lists. The current approach starts with illness severity, then uses the patient's own prior cultures, recent antibiotic exposure, organ function, allergies, and local susceptibility patterns to choose initial therapy. Culture-directed narrowing and early IV-to-oral transition support stewardship without sacrificing outcomes. The important exception is obstruction: fever and infection above an obstructed ureter or collecting system is a source-control emergency that requires drainage in addition to antimicrobial treatment.

References

1. IDSA 2025 Guideline Update on Complicated Urinary Tract Infections — Link